-
Kenya's economy faces climate change risks: World Bank
-
Milei demands expulsion of foreigners expressing 'hate' against Argentina
-
'Beginning of the end': Relief but no party as French wildfire winds down
-
Italy's Po River valley on drought alert
-
Southern Europe 'becoming more flammable' in hotter climate, experts say
-
Prada profits pinched as growth hard to chase
-
Mammoth bones found on parched bed of Danube in Bulgaria
-
Stocks climb on earnings and rates, oil retreats
-
MEXC Lists Grvt (GRVT) with $60,000 Worth of GRVT and 10,000 USDT in Airdrop+ Rewards
-
US economic growth slows in second quarter, missing expectations
-
George and Amal Clooney flee French home due to wildfire
-
Russia adds Telegram founder Durov to 'terrorist' blacklist
-
MEXC Ventures Supports Alpha Arena's APAC Debut at Coinfest Bali
-
Stocks diverge on earnings, as oil steadies
-
AI data centre supplier Zhongji InnoLight slips on Hong Kong debut
-
Eurozone economy grows despite Middle East war
-
May, June heatwaves caused 2,877 extra deaths in England: govt
-
Singapore group will develop 'most promising' Ebola vaccine
-
BMW profit down a third as carmaker plans job cuts
-
Shell profit surges as Mideast war fuels oil prices
-
Seoul extends losses as most Asian markets drop, oil rises again
-
Car maker Stellantis says back in profit in second quarter
-
Gambling.com Group Is Now Grandstand
-
Samsung quarterly operating profit up 1,800% on AI boom
-
Meet the astronomer digging into the Milky Way's 'fossils'
-
South Korean stocks bounce after rout, oil holds gains on Mideast woes
-
AI data centre supplier Zhongji InnoLight falls on Hong Kong debut
-
South Korea's women web sleuths fight AI deepfake porn
-
Samsung operating profit up 1,800% in second quarter on AI boom
-
Anything but programmable: New cost-efficient EC-power-supply-series for the DIN rail by CAMTEC PS
-
Japanese population below 120 million for first time in decades
-
Meta misses profit expectations, sticks to massive AI spending
-
US actor Jared Leto denies latest accusations of sexual assault
-
Campari - king of the spritz - hopes to conquer American heartland
-
Danube drops to 'historic lows' as fresh heatwave hits
-
Air France-KLM and Lufthansa bid for Portugal's TAP airline
-
BTS pulls out of Grammys after Asian pop category introduction
-
Profits soar at Airbus as it delivers more planes
-
OpenAI says rogue AI agent attack hit other companies
-
Rheinmetall shares surge after armsmaker reports record profit
-
How an AFP beach snap became emblem of Europe's wildfire summer
-
FIFA hit by furious backlash over plans to sell stake in competitions
-
TRX Spot and Perpetuals Listing Launches on Backpack, Expanding Access to the TRON Ecosystem
-
MEXC Integrates World-Check to Fortify Institutional Grade Compliance Architecture
-
Nepal's tiger numbers climb 20 percent to estimated 429: survey
-
Spain returns wildfire evacuees as France braces for worsening weather
-
FIFA's plans to sell $4.2bn stake in its tournaments widely criticised
-
Russia seeks arrest of Telegram chief Durov
-
BMW aims to cut 8,000 jobs by end 2027: company source
-
South Korean stocks plunge as tech rout deepens, oil rises
Ozempic slimming craze sweeps Kosovo despite side effects
Kosovo influencer Tringa Kadriu sees the slimming drug Ozempic as a chance to shed excess pounds -- and she is not the only one in her Balkan nation, where more than half the population is overweight.
"I want to lose 15-16 kilos (33-35 pounds) in two months," Kadriu, 29, told AFP, "and then I'll continue with fitness".
Ozempic, approved in the United States to treat diabetes in 2017, has found an international market for people trying to lose weight.
Despite its cost, the drug has soared in popularity in Kosovo, a country of 1.7 million.
While Kosovo authorities have not sanctioned the drug's use for weight loss, they have noted their limited means to confront use of a drug widely available in the country.
Merita Emini-Sadiku, who heads the Kosovo university hospital's endocrinology clinic, said the cost of the drug had soared.
"The monthly dose used to be 75-80 euros ($85-91), while now it is 130-140 euros ($147-159), probably due to high demand," she said.
But she warned that "Ozempic has side effects that people are not aware of".
Ozempic use can potentially cause issues including thyroid cancer, pancreatitis, gastroparesis and bowel obstruction, according to the latest studies.
- 'Constant demand' -
Meant to treat Type 2 diabetes -- of which the WHO says Kosovo has lower than average levels -- the drug regulates blood sugar levels but also helps suppress hunger, leading to a lower calorie intake.
As a result, its potentially cancerous complications have done little to stem the drug's popularity or availability.
"I checked a lot of pharmacies in Kosovo and I noticed that Ozempic is very easy to get," said Kadriu, adding that pharmacists even suggested she gradually increase her dosage.
A worker at a pharmacy in the capital Pristina's downtown, who asked to remain anonymous, said she had trouble recalling when someone last came into her pharmacy to buy Ozempic with a diabetes prescription.
"But we have a constant demand for Ozempic without a prescription. You can guess why," she said.
Given its availability, Emini-Sadiku said authorities should exercise greater control over Ozempic's distribution.
But Bujar Vitija, a journalist specialising in health, said that would be tricky to achieve given Kosovo's poor health record-keeping.
"Unfortunately there is no data," Vitija said.
With 1,500 to 1,600 private pharmacies in Kosovo, the country's 20 pharmaceutical inspectors have their work cut out for them, he added.
- Ozempic 'every day' -
While Kosovo has lower levels of obesity than the European average, more than 57 percent of the population is overweight and 20 percent is clinically obese, according to a 2019 World Health Organization report.
And women, who are more likely to face societal pressure to be thin, were 66 percent more likely to be obese than men, the WHO report found.
But not every Kosovar who has used Ozempic had the best experience with the drug.
"I took Ozempic on the advice of a doctor for two years but it had no effect," said 48-year-old merchant Lulzim Rrahmani, adding that three of his relatives even experienced "a negative effect of the drug".
"It was just a waste of money and time."
Given the risk of side effects, Emini-Sadiku said Ozempic was "by no means to be taken without a doctor's prescription".
Yet Kadriu said she would not be deterred, adding that she saw colleagues taking the drug "every day at work".
"I don't see any symptom that would deter me."
X.Wong--CPN